Compare Sana Biotechnology Inc (SANA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs ProShares UltraPro S&P500 — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while ProShares UltraPro S&P500 trades at $154.51. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | UPRO | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $5.92 | $155.10 |
52-Week Low | $2.68 | $89.29 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
UPRO trades at $154.55, down 0.28% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF shows strong institutional interest with Bay Colony Advisors establishing a new position. Market sentiment is mixed as the S&P 500 faces valuation concerns at record highs, with the Fear & Greed index indicating greed zone conditions amid inflation data anticipation.
The leveraged ETF's performance remains tied to S&P 500 momentum, with technical support at $150-$152 providing downside protection. Key risks include market volatility and overbought conditions, while institutional accumulation suggests confidence in near-term upside potential despite broader market valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
